<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253409</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000448615</org_study_id>
    <secondary_id>ICR-CTSU-MARS</secondary_id>
    <secondary_id>EU-20532</secondary_id>
    <nct_id>NCT00253409</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery</brief_title>
  <official_title>Mesothelioma and Radical Surgery Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy&#xD;
      x-rays to kill tumor cells. Giving combination chemotherapy before surgery may shrink the&#xD;
      tumor so that it can be removed. Giving radiation therapy after surgery may kill any tumor&#xD;
      cells that remain after surgery. It is not yet known whether combination chemotherapy is more&#xD;
      effective with or without surgery and radiation therapy in treating mesothelioma.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying combination chemotherapy, surgery, and&#xD;
      radiation therapy to see how well they work compared to combination chemotherapy alone in&#xD;
      treating patients with mesothelioma that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the feasibility of neoadjuvant combination chemotherapy with vs without surgery&#xD;
           and adjuvant radiotherapy in patients with resectable malignant mesothelioma.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter, pilot study followed by a randomized, controlled study.&#xD;
&#xD;
      Patients undergo 3 courses of a platinum-based (cisplatin or carboplatin) combination&#xD;
      chemotherapy regimen to be determined by the treatment center. Upon completion of combination&#xD;
      chemotherapy, patients are randomized to 1 of 2 treatment arms provided tumor is resectable&#xD;
      and there is no disease progression.&#xD;
&#xD;
        -  Arm I: Patients undergo extra-pleural pneumonectomy followed by post-operative&#xD;
           radiotherapy.&#xD;
&#xD;
        -  Arm II: Patients undergo follow-up only. Patients may receive additional standard&#xD;
           therapy according to their treatment center.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 3 months for 1 year, every 6 months for 1&#xD;
      year, and then annually thereafter.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 2 years and then&#xD;
      annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50-670 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">670</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically and immuno-histochemically confirmed malignant mesothelioma&#xD;
&#xD;
               -  Resectable disease (T1-3, N0-1, M0) with no distant metastases&#xD;
&#xD;
          -  Eligible to undergo extra-pleural pneumonectomy based on British Thoracic Society&#xD;
             guidelines&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Normal renal function&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 40%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Predicted post-operative FEV_1 ≥ 40%&#xD;
&#xD;
          -  Predicted post-operative DLCO ≥ 40%&#xD;
&#xD;
          -  No significant pulmonary hypertension&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No physical or personal condition that would preclude ability to undergo chemotherapy&#xD;
             or post-operative radiotherapy&#xD;
&#xD;
          -  No physical or personal condition that would preclude ability to comply with follow-up&#xD;
             requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clare Peckitt</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Cancer Research, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Burton-upon-Trent</city>
        <state>England</state>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB3 8RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berkshire Cancer Centre at Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <state>England</state>
        <zip>RG1 5AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cancer Research - Sutton</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>July 11, 2009</last_update_submitted>
  <last_update_submitted_qc>July 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2009</last_update_posted>
  <keyword>localized malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

